Vedanta Biosciences said Wednesday that a mid-stage trial of its VE202 drug candidate to treat ulcerative colitis did not meet its primary endpoint of endoscopic response.

VE202 was well tolerated, with no reports of serious adverse events, said Vedanta, a PureTech Health (PRTC) founded entity.

Vedanta said it remains focused on its lead program, VE303, for the prevention of recurrent clostridioides difficile infection.

Separately, PureTech said its stake in Vedanta has been diluted to 4.2% over the course of 2025.

Price: 18.20, Change: +0.87, Percent Change: +5.02